Urihk Pharmaceutical Private Limited

Urihk Pharmaceutical Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U51909MH2017FTC302652 Incorporated 08 December 2017 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Foreign Private Limited Company pharma Startup India MSME · Small
Data last updated
Revenue · FY 2025
₹8.62 Cr
▼ 19% YoY
Net loss · FY 2025
₹8.49 Cr
Net margin -98.5%
EBITDA · FY 2025
-₹7.8 Cr
EBITDA margin -90.5%
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹19.82 Cr
Issued & subscribed
Company age
9 yrs
Est. 2017
Employees · EPFO
79
Provident fund records
Directors on board
4
As per MCA filings

About Urihk Pharmaceutical Private Limited

Data last updated:

Urihk Pharmaceutical Private Limited is a foreign private limited company based in Mumbai, Maharashtra, India, a subsidiary of Ureka Hong Kong Limited and recognised as a startup by DPIIT. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 08 December 2017 and has been in existence for over 9 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2017FTC302652. Its GSTIN is 27AACCU1777F1Z8 (Maharashtra). The company holds 8 GST registrations, of which 7 are active.

The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹19.82 Cr. It is led by directors including Rajesh Madanlal Gupta (Whole-Time Director) and Tarun Gupta.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 603 Sai Samarth Business Park, Mumbai, Maharashtra.

As per the financials filed for FY 2025, the company reported a revenue of ₹8.62 Cr, a decline of 19% compared to the previous year. For the same year it recorded a net loss of ₹8.49 Cr (net margin -98.5%) and EBITDA of -₹7.8 Cr (EBITDA margin -90.5%). Revenue has declined at a compounded annual rate (CAGR) of 36% over three years and 3% over five years.

The company has about 79 employees on its provident fund (EPFO) records.

Urihk Pharmaceutical Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0005507). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website urihkpharma.com.

Company Details of Urihk Pharmaceutical Private Limited
CIN U51909MH2017FTC302652
Registration Number 302652
Incorporation Date 08 December 2017
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Ureka Hong Kong Limited
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification Small
Udyam Registration UDYAM-MH-18-0005507

Recognitions & Rankings of Urihk Pharmaceutical

Startup India Government of India
MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-18-0005507
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Social Media
  • Registered Address
    Office No. 602 – 603 Sai Samarth Business Park Near Wasan Motors Deonar Govandi (East, ), Mumbai, Maharashtra, India – 400088
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors
Comprehensive company report
Urihk Pharmaceutical Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full report on Urihk Pharmaceutical

Financials, compliance, directors, charges, ownership and filings for Urihk Pharmaceutical Private Limited in one report.

Financials from FY 2018 Directors & ownership Charges & compliance

Business Activity

The main business activity of Urihk Pharmaceutical is trade. In detail, this covers wholesale trading.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
GTradeG1Wholesale TradingLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Financials of Urihk Pharmaceutical Private Limited

FY 2025 filings available

Urihk Pharmaceutical Private Limited reported revenue of ₹8.62 Cr (down 19% YoY) for FY 2025.

Revenue · FY 2025
₹8.62 Cr ▼ 19%
Net loss · FY 2025
₹8.49 Cr margin -98.5%
EBITDA · FY 2025
-₹7.8 Cr margin -90.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 19%
3 years · compounded
▼ 36%
5 years · compounded
▼ 3%
EBITDA CAGR growth
1 year
▲ 54%
3 years · compounded
▲ 7%
5 years · compounded
▲ 10%

Revenue has declined at a compounded annual rate (CAGR) of 3% over five years, including a 19% fall in the latest year. EBITDA rose 54% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2020-21 to FY 2023-24in the company report
Profit and Loss Statement
Revenue from Operations••••
Other Income••••
Total Revenue••••
Cost of Materials Consumed••••
Employee Benefit Expense••••
Finance Costs••••
Depreciation and Amortisation••••
Other Expenses••••
Total Expenses••••
EBITDA-₹7.8 Cr
Profit Before Tax••••
Tax Expense••••
Net Profit (PAT)-₹8.49 Cr
Balance Sheet
Share Capital••••
Reserves and Surplus••••
Net Worth (Total Equity)••••
Long-term Borrowings••••
Short-term Borrowings••••
Trade Payables••••
Total Liabilities••••
Fixed Assets••••
Investments••••
Inventories••••
Trade Receivables••••
Cash and Bank Balance••••
Total Assets••••

Financial Ratios

MetricsFY 2024-25FY 2020-21 to FY 2023-24in the company report
Profitability
EBITDA Margin-90.5%
Net Profit Margin-98.5%
Return on Equity (ROE)••••
Return on Capital Employed (ROCE)••••
Return on Assets (ROA)••••
Liquidity and Debt
Current Ratio••••
Quick Ratio••••
Debt-to-Equity Ratio••••
Interest Coverage Ratio••••
Efficiency and Growth
Asset Turnover••••
Receivable Days••••
Payable Days••••
Inventory Days••••
Revenue Growth••••
Net Profit Growth••••

Paid data: the figures shown as dots, and every line for FY 2020-21 to FY 2023-24, are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Urihk Pharmaceutical are in the company report.

Financial statements from FY 2018: available in the company report

Board of Directors of Urihk Pharmaceutical Private Limited

Urihk Pharmaceutical has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Rajesh Madanlal GuptaWhole-Time Director08 Dec 20178 Years 10 MonthsCurrent
Tarun GuptaDirector08 Dec 20178 Years 10 MonthsCurrent
Rajesh SharmaDirector01 Jan 20206 Years 9 MonthsCurrent
Xuekui ChenDirector13 Apr 20188 Years 6 MonthsCurrent

Peer Comparison

Urihk Pharmaceutical Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
MSK Pharmaceuticals Private Limited₹8.64 Cr (FY 2025)••••••••55.0%••••Saraipali, Chhattisgarh, India
Urihk Pharmaceutical Private Limited this company₹8.62 Cr (FY 2025)••••••••-19.0%••••Mumbai, Maharashtra, India
Orgyn Laboratories Private Limited₹8.59 Cr (FY 2025)••••••••18.0%••••New Delhi, Delhi, India
Biomed (I) Healthcare Private Limited₹8.58 Cr (FY 2019)••••••••-4.0%••••Hyderabad, Telangana, India
Modasa Pharmaceuticals Private Limited₹8.58 Cr (FY 2025)••••••••37.0%••••Modasa, Gujarat, India

Peers are the companies nearest to Urihk Pharmaceutical by revenue, above and below it, in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details

Urihk Pharmaceutical Private Limited is audited by A M JAIN & CO for the financial year 2023.

NameStatusAppointment DateCessation Date
A M JAIN & COLockedLockedLocked

Complete auditor history: available in the company report

Ownership and Shareholding

Shareholding and ownership data: available in the company report

Charges & Borrowings

Urihk Pharmaceutical Private Limited does not have any charges (loans) registered with the Registrar of Companies.

MSME Payment Delays

Urihk Pharmaceutical Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (1 of 1)

SupplierAmount dueDue sinceReported on
Pharmasofttech Awacs Private Limited••••••••••••

Full MSME payment history: available in the company report

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance

Urihk Pharmaceutical Private Limited has a workforce of 79 employees as of Mar 28, 2024.

Employee count
79
Active EPFO establishments
1
Employee growth
-15.05%

Employee and EPFO history: available in the company report

Recent Activity

Urihk Pharmaceutical Private Limited has 8 board changes on record since 2017: 4 appointments and 4 cessations. The latest: Rajesh Sharma ceased to be Additional Director on 09 Nov 2020.

AGM
Urihk Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Urihk Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Ceased
Rajesh Sharma ceased to be Additional Director.
Appointed
Rajesh Sharma was appointed as Director.
Ceased
Jaspinder Singh ceased to be Company Secretary.
Ceased
Xinpei Yu ceased to be Additional Director.
Ceased
Xuekui Chen ceased to be Additional Director.
Appointed
Xuekui Chen was appointed as Director.
Appointed
Rajesh Madanlal Gupta was appointed as Whole-Time Director.
Appointed
Tarun Gupta was appointed as Director.
Incorporation
08 Dec 2017
Urihk Pharmaceutical Private Limited was registered on 08 Dec 2017 with Roc Mumbai & aged 8 years 10 months as per MCA records.

Credit Ratings, Litigation & Regulatory Alerts

Credit ratings, litigation, and regulatory alerts: available in the company report

Subsidiaries & Group Companies

Corporate group structure: available in the company report

GST Compliance

Urihk Pharmaceutical has 8 GST registrations: 7 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
8
Active
7
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AACCU1777F1Z8MaharashtraActive30 Jan 2018
09AACCU1777F1Z6Uttar PradeshActive15 Sep 2021
06AACCU1777F1ZCHaryanaActive22 Sep 2021
29AACCU1777F1Z4KarnatakaActive04 Nov 2021

GST registrations and filing compliance: available in the company report

MCA Filings & Documents

MCA filings and documents: available in the company report

Frequently Asked Questions

Urihk Pharmaceutical is an active foreign private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 08 December 2017 (9+ years old) and is registered under CIN U51909MH2017FTC302652.

Urihk Pharmaceutical has 4 current directors:

The latest financial statements of Urihk Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.

The GSTIN of Urihk Pharmaceutical is 27AACCU1777F1Z8, registered in Maharashtra. The company has 8 GST registrations in all, of which 7 are active and 1 is cancelled or inactive. Other active GSTINs include 09AACCU1777F1Z6 (Uttar Pradesh), 06AACCU1777F1ZC (Haryana), 29AACCU1777F1Z4 (Karnataka).

The CIN (Corporate Identification Number) of Urihk Pharmaceutical is U51909MH2017FTC302652. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Urihk Pharmaceutical was incorporated on 08 December 2017, making it 9+ years old. It is registered with the Registrar of Companies, Mumbai.

The peers of Urihk Pharmaceutical by revenue are MSK Pharmaceuticals Private Limited, Orgyn Laboratories Private Limited, Biomed (I) Healthcare Private Limited, Modasa Pharmaceuticals Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).

Rajesh Sharma ceased to be Additional Director on 09 Nov 2020. Rajesh Sharma was appointed as Director on 01 Jan 2020. Jaspinder Singh ceased to be Company Secretary on 05 Sep 2019. Urihk Pharmaceutical has 8 board changes on record in total.

Yes, Urihk Pharmaceutical is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).

Yes, Urihk Pharmaceutical is registered as a small enterprise under Udyam registration (number: UDYAM-MH-18-0005507).

Urihk Pharmaceutical has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier. The latest return was filed on 22 Apr 2022.

Urihk Pharmaceutical can be reached through the website urihkpharma.com. Its registered office is in Mumbai, Maharashtra, India.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available